Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX

Cancer Science

Volumn 102, Issue 3, 2011, Pages 578-582

  Yoshida, Yoichiro ^a,b   Hasegawa, Junichi ^a   Nezu, Riichiro ^a   Kim, Yong Kook ^a   Hirota, Masaki ^a   Kawano, Kiyoshi ^a   Izumi, Hiroto ^c   Kohno, Kimitoshi ^c  

^a OSAKA ROSAI HOSPITAL   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MITOCHONDRIAL TRANSCRIPTION FACTOR A; OXALIPLATIN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79951689280     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01835.x     Document Type: Article

References (29)

1. Satoh M, Kuroiwa T. Organization of multiple nucleoids and DNA molecules in mitochondria of a human cell. Exp Cell Res 1998; 196: 137-40.
2. Anderson S, Bankier AT, Barriel BG et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290: 457-65.
3. Olivero OA, Semino C, Kassim A et al. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res 1995; 346: 221-30.
4. Meijera C, van Luyn MJ, Nienhuis EF et al. Ultrastructural morphology and localisation of cisplatin-induced platinum-DNA adducts in a cisplatin-sensitive and -resistant human small cell lung cancer cell line using electron microscopy. Biochem Pharmacol 2001; 61: 573-8.
5. Murata T, Hibasami H, Maekawa S et al. Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem Int 1990; 20: 949-55.
6. Giurgiovich AJ, Diwan BA, Olivero OA et al. Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure. Carcinogenesis 1997; 18: 93-6.
7. Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem 1998; 26: 1175-212.
8. LeDoux SP, Wilson GL, Beecham EJ et al. Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis 1992; 13: 1967-73.
9. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695-8.
10. Yoshida Y, Izumi H, Torigoe T et al. p53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res 2003; 63: 3729-34.
11. O'Dwyer PJ, Johnson SW. Current status of oxaliplatin in colorectal cancer. Semin Oncol 2003; 30: 78-87.
12. Chaney SG, Campbell SL, Bassett E et al. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005; 53: 3-11.
13. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99: 2467-98.
14. Gourdier I, Crabbe L, Andreau K et al. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 2004; 23: 7449-57.
15. Parisi MA, Clayton DA. Similarity of human mitochondrial transcription factor 1 to high mobility group proteins. Science 1991; 252: 965-9.
16. Pil PM, Lippard SJ. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 1992; 256: 234-7.
17. Hughes EN, Engelsberg BN, Billings BN. Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2. J Biol Chem 1992; 267: 13520-7.
18. Bilings PC, Davis RJ, Engelsberg RJ et al. Characterization of high mobility group protein binding to cisplatin-damaged DNA. Biochem Biophys Res Commun 1992; 188: 1286-94.
19. Turchi JJ, Li M, Henkels KM. Cisplatin-DNA binding specificity of calf high mobility group 1 protein. Biochemistry 1996; 35: 2992-3000.
20. Larsson NG, Wang J, Wilhemsson H et al. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet 1998; 18: 231-6.
21. Wang J, Silva JP, Gustafsson CM et al. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc Natl Acad Sci USA 2001; 98: 4038-43.
22. Ohno T, Umeda S, Hamasaki N et al. Binding of human mitochondrial transcription factor A, an HMG box protein, to a four-way DNA junction. Biochem Biophys Res Commun 2000; 271: 492-8.
23. Yoshida Y, Izumi H, Ise T et al. Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA. Biochem Biophys Res Commun 2002; 295: 945-51.
24. Ueta E, Sasabe E, Yang Z et al. Enhancement of apoptotic damage of squamous cell carcinoma cells by inhibition of the mitochondrial DNA repairing system. Cancer Sci 2008; 99: 2230-7.
25. Shibao K, Izumi H, Nakayama Y et al. Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer 2002; 94: 1939-46.
26. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-8.
27. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 117-20.
28. Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 1980; 30: 151-69.
29. Fink D, Zheng H, Nebel S et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997; 57: 1841-5.